R. R. Williams

发表

Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

A. Chow, J. Natarajan, R. R. Williams, 2001, Antimicrobial Agents and Chemotherapy.

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects

S. Chien, A. Chow, J. Natarajan, 1997, Antimicrobial agents and chemotherapy.

Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers

S. Chien, A. Chow, R. R. Williams, 1998, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

S. Chien, A. Chow, J. Natarajan, 1997, Antimicrobial agents and chemotherapy.

Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics.

E. McClelland, R. Moss, N. Adkinson, 1991, Reviews of infectious diseases.

Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.

T. Marrie, R. R. Williams, C. Fogarty, 2001, Clinical therapeutics.

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

T. File, R. R. Williams, J. Segreti, 1997, Antimicrobial agents and chemotherapy.

An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.

B. Parasuraman, R. R. Williams, B. Rittenhouse, 2000, The American journal of managed care.

Absence of a pharmacokinetic interaction between digoxin and levofloxacin

A. Chow, J. Natarajan, R. R. Williams, 2002, Journal of clinical pharmacy and therapeutics.

ONCE A DAY LEVOFLOXACIN IN THE TREATMENT OF MILD TO MODERATE AND SEVERE COMMUNITY‐ACQUIRED PNEUMONIA IN ADULTS

R. R. Williams, C. Fogarty, A. Rubin, 1998 .

Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin

J. Natarajan, R. R. Williams, C. Fowler, 1997, Journal of clinical pharmacology.

Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis

L. Gentry, R. R. Williams, M. Habib, 1998 .

Levofloxacin Does Not Alter Cyclosporine Disposition

S. Chien, R. Nayak, D. Doose, 1998, Journal of clinical pharmacology.

Multicenter, Randomized Study Comparing Levofloxacin and Ciprofloxacin for Uncomplicated Skin and Skin Structure Infections

Jeffrey W. Smith, L. Gentry, R. R. Williams, 1997, Southern medical journal.

Comparing the Efficacy and Safety of Intravenous and / or Oral Levofloxacin versus Ceftriaxone and / or Cefuroxime Axetil in Treatment of Adults with Community-Acquired Pneumonia

R. R. Williams, J. Segreti, L. Dunbar, 1997 .

Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections.

D. Hotchkin, R. R. Williams, 1991, Reviews of infectious diseases.

Aztreonam in the treatment of gram-negative bacterial meningitis.

A. Lentnek, R. R. Williams, 1991, Reviews of infectious diseases.

Cost containment of the second-generation cephalosporins by prospective monitoring at a community teaching hospital.

R. R. Williams, P. Gross, J. Levine, 1985, Archives of internal medicine.